Colon cancer (adenocarcinoma of the colon)
Prepared with OnCo (onco.cc/prep/colon-cancer/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
15 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Mismatch repair and microsatellite instability, RAS and BRAF V600E mutation, HER2 amplification, Primary tumour side, Circulating tumour DNA after surgery, Carcinoembryonic antigen), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (stage i to iii), which of the standard options do you recommend and why?
- 6.Am I a candidate for FOLFOX (5-FU, leucovorin, oxaliplatin), CAPOX (capecitabine, oxaliplatin), and what side effects should I expect?
- 7.How do the results of DYNAMIC and CIRCULATE-US apply to someone like me?
- 8.For my situation (mismatch-repair deficient, localised), which of the standard options do you recommend and why?
- 9.Am I a candidate for Nivolumab, Ipilimumab, and what side effects should I expect?
- 10.How do the results of NICHE-2 and ATOMIC (Alliance A021502) apply to someone like me?
- 11.For my situation (metastatic), which of the standard options do you recommend and why?
- 12.Am I a candidate for Cetuximab, Panitumumab, Bevacizumab, and what side effects should I expect?
- 13.How do the results of PARADIGM apply to someone like me?
- 14.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 15.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Tests and results to bring
Biomarker results to ask for: Mismatch repair and microsatellite instability, RAS and BRAF V600E mutation, HER2 amplification (metastatic), Primary tumour side, Circulating tumour DNA after surgery, Carcinoembryonic antigen.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Stage I to III: Colectomy with regional lymphadenectomy; adjuvant FOLFOX or CAPOX for stage III and high-risk stage II, with ctDNA guidance under study. (FOLFOX (5-FU, leucovorin, oxaliplatin), CAPOX (capecitabine, oxaliplatin), DYNAMIC, CIRCULATE-US, CHALLENGE (CCTG CO.21))
- Mismatch-repair deficient, localised: Neoadjuvant nivolumab and ipilimumab (NICHE-2) and adjuvant atezolizumab with FOLFOX (ATOMIC) in trials. (NICHE-2, ATOMIC (Alliance A021502), Nivolumab, Ipilimumab)
- Metastatic: As the colorectal page by sidedness and RAS, BRAF and HER2 status. (Colorectal cancer, Cetuximab, Panitumumab, Bevacizumab, PARADIGM)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.